▶ 調査レポート

世界のヒト用ワクチンのアジュバント市場インサイト・予測(~2027年)

• 英文タイトル:Global Human Vaccine Adjuvants Market Insights, Forecast to 2027

QYResearchが調査・発行した産業分析レポートです。世界のヒト用ワクチンのアジュバント市場インサイト・予測(~2027年) / Global Human Vaccine Adjuvants Market Insights, Forecast to 2027 / MRC840027Q資料のイメージです。• レポートコード:MRC840027Q
• 出版社/出版日:QYResearch / 2021年2月
• レポート形態:英文、PDF、116ページ
• 納品方法:Eメール(受注後3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥519,400 (USD4,900)▷ お問い合わせ
  Enterprise License¥1,038,800 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要

The global Human Vaccine Adjuvants market is valued at US$ XX million in 2020. The market size will reach US$ XX million by the end of 2027, growing at a CAGR of XX during 2021-2027.
Human Vaccine Adjuvants market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Human Vaccine Adjuvants market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type, and by Application for the period 2016-2027.

Segment by Type
 Oral
 Subcutaneous
 Intramuscular
 Others

Segment by Application
 Research Applications
 Commercial Applications

Segment by Region
 North America
 the United States
 Canada
 Asia-Pacific
 China
 Japan
 South Korea
 India
 Australia
 Taiwan
 Indonesia
 Thailand
 Malaysia
 Europe
 Germany
 France
 UK
 Italy
 Russia
 Latin America
 Mexico
 Brazil
 Argentina
 Middle East & Africa
 Turkey
 Saudi Arabia
 UAE

By Company
 GSK
 CSL Limited
 Brenntag Biosector
 SEPPIC
 SPI Pharma
 Novavax
 Avanti Polar Lipids
 Aphios

レポート目次

1 STUDY COVERAGE
1.1 Human Vaccine Adjuvants Product Introduction
1.2 Market by Type
1.2.1 Global Human Vaccine Adjuvants Market Size Growth Rate by Type
1.2.2 Oral
1.2.3 Subcutaneous
1.2.4 Intramuscular
1.2.5 Others
1.3 Market by Application
1.3.1 Global Human Vaccine Adjuvants Market Size Growth Rate by Application
1.3.2 Research Applications
1.3.3 Commercial Applications
1.4 Study Objectives
1.5 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Human Vaccine Adjuvants Sales Estimates and Forecasts 2016-2027
2.2 Global Human Vaccine Adjuvants Revenue Estimates and Forecasts 2016-2027
2.3 Global Human Vaccine Adjuvants Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Human Vaccine Adjuvants Regions by Sales
2.4.1 Global Top Human Vaccine Adjuvants Regions by Sales (2016-2021)
2.4.2 Global Top Human Vaccine Adjuvants Regions by Sales (2022-2027)
2.5 Global Top Human Vaccine Adjuvants Regions by Revenue
2.5.1 Global Top Human Vaccine Adjuvants Regions by Revenue (2016-2021)
2.5.2 Global Top Human Vaccine Adjuvants Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 COMPETITION BY MANUFACTURERS
3.1 Global Human Vaccine Adjuvants Sales by Manufacturers
3.1.1 Global Top Human Vaccine Adjuvants Manufacturers by Sales (2016-2021)
3.1.2 Global Top Human Vaccine Adjuvants Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Human Vaccine Adjuvants Sales in 2020
3.2 Global Human Vaccine Adjuvants Revenue by Manufacturers
3.2.1 Global Top Human Vaccine Adjuvants Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Human Vaccine Adjuvants Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Human Vaccine Adjuvants Revenue in 2020
3.3 Global Human Vaccine Adjuvants Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Human Vaccine Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Human Vaccine Adjuvants Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 MARKET SIZE BY TYPE
4.1 Global Human Vaccine Adjuvants Sales by Type
4.1.1 Global Human Vaccine Adjuvants Historical Sales by Type (2016-2021)
4.1.2 Global Human Vaccine Adjuvants Forecasted Sales by Type (2022-2027)
4.1.3 Global Human Vaccine Adjuvants Sales Market Share by Type (2016-2027)
4.2 Global Human Vaccine Adjuvants Revenue by Type
4.2.1 Global Human Vaccine Adjuvants Historical Revenue by Type (2016-2021)
4.2.2 Global Human Vaccine Adjuvants Forecasted Revenue by Type (2022-2027)
4.2.3 Global Human Vaccine Adjuvants Revenue Market Share by Type (2016-2027)
4.3 Global Human Vaccine Adjuvants Price by Type
4.3.1 Global Human Vaccine Adjuvants Price by Type (2016-2021)
4.3.2 Global Human Vaccine Adjuvants Price Forecast by Type (2022-2027)
5 MARKET SIZE BY APPLICATION
5.1 Global Human Vaccine Adjuvants Sales by Application
5.1.1 Global Human Vaccine Adjuvants Historical Sales by Application (2016-2021)
5.1.2 Global Human Vaccine Adjuvants Forecasted Sales by Application (2022-2027)
5.1.3 Global Human Vaccine Adjuvants Sales Market Share by Application (2016-2027)
5.2 Global Human Vaccine Adjuvants Revenue by Application
5.2.1 Global Human Vaccine Adjuvants Historical Revenue by Application (2016-2021)
5.2.2 Global Human Vaccine Adjuvants Forecasted Revenue by Application (2022-2027)
5.2.3 Global Human Vaccine Adjuvants Revenue Market Share by Application (2016-2027)
5.3 Global Human Vaccine Adjuvants Price by Application
5.3.1 Global Human Vaccine Adjuvants Price by Application (2016-2021)
5.3.2 Global Human Vaccine Adjuvants Price Forecast by Application (2022-2027)
6 NORTH AMERICA
6.1 North America Human Vaccine Adjuvants Market Size by Type
6.1.1 North America Human Vaccine Adjuvants Sales by Type (2016-2027)
6.1.2 North America Human Vaccine Adjuvants Revenue by Type (2016-2027)
6.2 North America Human Vaccine Adjuvants Market Size by Application
6.2.1 North America Human Vaccine Adjuvants Sales by Application (2016-2027)
6.2.2 North America Human Vaccine Adjuvants Revenue by Application (2016-2027)
6.3 North America Human Vaccine Adjuvants Market Size by Country
6.3.1 North America Human Vaccine Adjuvants Sales by Country (2016-2027)
6.3.2 North America Human Vaccine Adjuvants Revenue by Country (2016-2027)
6.3.3 the United States
6.3.4 Canada
7 EUROPE
7.1 Europe Human Vaccine Adjuvants Market Size by Type
7.1.1 Europe Human Vaccine Adjuvants Sales by Type (2016-2027)
7.1.2 Europe Human Vaccine Adjuvants Revenue by Type (2016-2027)
7.2 Europe Human Vaccine Adjuvants Market Size by Application
7.2.1 Europe Human Vaccine Adjuvants Sales by Application (2016-2027)
7.2.2 Europe Human Vaccine Adjuvants Revenue by Application (2016-2027)
7.3 Europe Human Vaccine Adjuvants Market Size by Country
7.3.1 Europe Human Vaccine Adjuvants Sales by Country (2016-2027)
7.3.2 Europe Human Vaccine Adjuvants Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 UK
7.3.6 Italy
7.3.7 Russia
8 ASIA PACIFIC
8.1 Asia Pacific Human Vaccine Adjuvants Market Size by Type
8.1.1 Asia Pacific Human Vaccine Adjuvants Sales by Type (2016-2027)
8.1.2 Asia Pacific Human Vaccine Adjuvants Revenue by Type (2016-2027)
8.2 Asia Pacific Human Vaccine Adjuvants Market Size by Application
8.2.1 Asia Pacific Human Vaccine Adjuvants Sales by Application (2016-2027)
8.2.2 Asia Pacific Human Vaccine Adjuvants Revenue by Application (2016-2027)
8.3 Asia Pacific Human Vaccine Adjuvants Market Size by Region
8.3.1 Asia Pacific Human Vaccine Adjuvants Sales by Region (2016-2027)
8.3.2 Asia Pacific Human Vaccine Adjuvants Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 LATIN AMERICA
9.1 Latin America Human Vaccine Adjuvants Market Size by Type
9.1.1 Latin America Human Vaccine Adjuvants Sales by Type (2016-2027)
9.1.2 Latin America Human Vaccine Adjuvants Revenue by Type (2016-2027)
9.2 Latin America Human Vaccine Adjuvants Market Size by Application
9.2.1 Latin America Human Vaccine Adjuvants Sales by Application (2016-2027)
9.2.2 Latin America Human Vaccine Adjuvants Revenue by Application (2016-2027)
9.3 Latin America Human Vaccine Adjuvants Market Size by Country
9.3.1 Latin America Human Vaccine Adjuvants Sales by Country (2016-2027)
9.3.2 Latin America Human Vaccine Adjuvants Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Human Vaccine Adjuvants Market Size by Type
10.1.1 Middle East and Africa Human Vaccine Adjuvants Sales by Type (2016-2027)
10.1.2 Middle East and Africa Human Vaccine Adjuvants Revenue by Type (2016-2027)
10.2 Middle East and Africa Human Vaccine Adjuvants Market Size by Application
10.2.1 Middle East and Africa Human Vaccine Adjuvants Sales by Application (2016-2027)
10.2.2 Middle East and Africa Human Vaccine Adjuvants Revenue by Application (2016-2027)
10.3 Middle East and Africa Human Vaccine Adjuvants Market Size by Country
10.3.1 Middle East and Africa Human Vaccine Adjuvants Sales by Country (2016-2027)
10.3.2 Middle East and Africa Human Vaccine Adjuvants Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 UAE
11 CORPORATE PROFILE
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Overview
11.1.3 GSK Human Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 GSK Human Vaccine Adjuvants Product Description
11.1.5 GSK Recent Developments
11.2 CSL Limited
11.2.1 CSL Limited Corporation Information
11.2.2 CSL Limited Overview
11.2.3 CSL Limited Human Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 CSL Limited Human Vaccine Adjuvants Product Description
11.2.5 CSL Limited Recent Developments
11.3 Brenntag Biosector
11.3.1 Brenntag Biosector Corporation Information
11.3.2 Brenntag Biosector Overview
11.3.3 Brenntag Biosector Human Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Brenntag Biosector Human Vaccine Adjuvants Product Description
11.3.5 Brenntag Biosector Recent Developments
11.4 SEPPIC
11.4.1 SEPPIC Corporation Information
11.4.2 SEPPIC Overview
11.4.3 SEPPIC Human Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 SEPPIC Human Vaccine Adjuvants Product Description
11.4.5 SEPPIC Recent Developments
11.5 SPI Pharma
11.5.1 SPI Pharma Corporation Information
11.5.2 SPI Pharma Overview
11.5.3 SPI Pharma Human Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 SPI Pharma Human Vaccine Adjuvants Product Description
11.5.5 SPI Pharma Recent Developments
11.6 Novavax
11.6.1 Novavax Corporation Information
11.6.2 Novavax Overview
11.6.3 Novavax Human Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Novavax Human Vaccine Adjuvants Product Description
11.6.5 Novavax Recent Developments
11.7 Avanti Polar Lipids
11.7.1 Avanti Polar Lipids Corporation Information
11.7.2 Avanti Polar Lipids Overview
11.7.3 Avanti Polar Lipids Human Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Avanti Polar Lipids Human Vaccine Adjuvants Product Description
11.7.5 Avanti Polar Lipids Recent Developments
11.8 Aphios
11.8.1 Aphios Corporation Information
11.8.2 Aphios Overview
11.8.3 Aphios Human Vaccine Adjuvants Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Aphios Human Vaccine Adjuvants Product Description
11.8.5 Aphios Recent Developments
12 VALUE CHAIN AND SALES CHANNELS ANALYSIS
12.1 Human Vaccine Adjuvants Value Chain Analysis
12.2 Human Vaccine Adjuvants Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Vaccine Adjuvants Production Mode & Process
12.4 Human Vaccine Adjuvants Sales and Marketing
12.4.1 Human Vaccine Adjuvants Sales Channels
12.4.2 Human Vaccine Adjuvants Distributors
12.5 Human Vaccine Adjuvants Customers
13 MARKET DRIVERS, OPPORTUNITIES, CHALLENGES AND RISKS FACTORS ANALYSIS
13.1 Human Vaccine Adjuvants Industry Trends
13.2 Human Vaccine Adjuvants Market Drivers
13.3 Human Vaccine Adjuvants Market Challenges
13.4 Human Vaccine Adjuvants Market Restraints
14 KEY FINDINGS IN THE GLOBAL HUMAN VACCINE ADJUVANTS STUDY
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer